A Facebook post sets the social media buzz aside and points to phase three trial results for three GLP-1 drugs, with weight loss reaching as high as 28%.
Recap by typeshit. Post by Facebook on Facebook.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Demócrata reports Lilly's oral GLP-1 met cardiovascular safety and lowered blood sugar and weight in type 2 diabetes. Few details beyond the headline.
Nearly 250 NAION cases sit in Pennsylvania federal court with hundreds more in New Jersey. Relkin, co-lead counsel, points to a baseline eye exam before starting a GLP-1.
Loading…